218 related articles for article (PubMed ID: 31162107)
1. Master protocols in clinical trials: a universal Swiss Army knife?
Sudhop T; Brun NC; Riedel C; Rosso A; Broich K; Senderovitz T
Lancet Oncol; 2019 Jun; 20(6):e336-e342. PubMed ID: 31162107
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.
Park JJH; Siden E; Zoratti MJ; Dron L; Harari O; Singer J; Lester RT; Thorlund K; Mills EJ
Trials; 2019 Sep; 20(1):572. PubMed ID: 31533793
[TBL] [Abstract][Full Text] [Related]
3. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
5. Umbrella and basket trials in oncology: ethical challenges.
Strzebonska K; Waligora M
BMC Med Ethics; 2019 Aug; 20(1):58. PubMed ID: 31443704
[TBL] [Abstract][Full Text] [Related]
6. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.
Meyer EL; Mesenbrink P; Dunger-Baldauf C; Fülle HJ; Glimm E; Li Y; Posch M; König F
Clin Ther; 2020 Jul; 42(7):1330-1360. PubMed ID: 32622783
[TBL] [Abstract][Full Text] [Related]
7. Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols.
Khan T; Stewart M; Blackman S; Rousseau R; Donoghue M; Cohen K; Seibel N; Fleury M; Benettaib B; Malik R; Vassal G; Reaman G
Ther Innov Regul Sci; 2019 Mar; 53(2):270-278. PubMed ID: 29759018
[TBL] [Abstract][Full Text] [Related]
8. An overview of precision oncology basket and umbrella trials for clinicians.
Park JJH; Hsu G; Siden EG; Thorlund K; Mills EJ
CA Cancer J Clin; 2020 Mar; 70(2):125-137. PubMed ID: 32031692
[TBL] [Abstract][Full Text] [Related]
9. Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials.
Yee LM; McShane LM; Freidlin B; Mooney MM; Korn EL
Cancer J; 2019; 25(4):254-263. PubMed ID: 31335389
[TBL] [Abstract][Full Text] [Related]
10. Designing clinical protocols for optimal use: measuring attributes of treatment and cancer control trials.
Veney JE; Kory WP; Barnsley JM; Kaluzny AD
J Med Syst; 1991 Dec; 15(5-6):335-44. PubMed ID: 1812186
[TBL] [Abstract][Full Text] [Related]
11. Challenges and approaches to implementing master/basket trials in oncology.
Burd A; Schilsky RL; Byrd JC; Levine RL; Papadimitrakopoulou VA; Herbst RS; Redman MW; Druker BJ; Gandara DR
Blood Adv; 2019 Jul; 3(14):2237-2243. PubMed ID: 31337605
[TBL] [Abstract][Full Text] [Related]
12. Definitions and statistical properties of master protocols for personalized medicine in oncology.
Renfro LA; Mandrekar SJ
J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
[TBL] [Abstract][Full Text] [Related]
13. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
14. Unlocking the Potential: A Systematic Review of Master Protocol in Pediatrics.
Li Y; Nelson R; Izem R; Broglio K; Mundayat R; Gamalo M; Wen Y; Pan H; Sun H; Ye J
Ther Innov Regul Sci; 2024 Jul; 58(4):634-644. PubMed ID: 38653950
[TBL] [Abstract][Full Text] [Related]
15. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
Hwang TJ; Tomasi PA; Bourgeois FT
PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
[TBL] [Abstract][Full Text] [Related]
16. Challenges with Novel Clinical Trial Designs: Master Protocols.
Cecchini M; Rubin EH; Blumenthal GM; Ayalew K; Burris HA; Russell-Einhorn M; Dillon H; Lyerly HK; Reaman GH; Boerner S; LoRusso PM
Clin Cancer Res; 2019 Apr; 25(7):2049-2057. PubMed ID: 30696689
[TBL] [Abstract][Full Text] [Related]
17. Demystifying the estimand framework: a case study using patient-reported outcomes in oncology.
Fiero MH; Pe M; Weinstock C; King-Kallimanis BL; Komo S; Klepin HD; Gray SW; Bottomley A; Kluetz PG; Sridhara R
Lancet Oncol; 2020 Oct; 21(10):e488-e494. PubMed ID: 33002444
[TBL] [Abstract][Full Text] [Related]
18. Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials.
Lu CC; Li XN; Broglio K; Bycott P; Jiang Q; Li X; McGlothlin A; Tian H; Ye J
Ther Innov Regul Sci; 2021 Nov; 55(6):1145-1154. PubMed ID: 34160785
[TBL] [Abstract][Full Text] [Related]
19. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Issues of Platform Trials: Learnings from EU-PEARL.
Nguyen QL; Hees K; Hernandez Penna S; König F; Posch M; Bofill Roig M; Meyer EL; Freitag MM; Parke T; Otte M; Dauben HP; Mielke T; Spiertz C; Mesenbrink P; Gidh-Jain M; Pierre S; Morello S; Hofner B
Clin Pharmacol Ther; 2024 Jul; 116(1):52-63. PubMed ID: 38529786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
